Unicycive Therapeutics Inc
UNCY
Get informed when a big investor buys or sells
+ FollowMarket Cap$140.58M
Close$
$1.83
65.6% downside
Current Fair Value
65.6% downsideOvervalued by 65.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $140.58 Million |
|---|---|
| Enterprise Value | $97.06 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.67 |
| Beta | 1.78 |
| Outstanding Shares | 26,917,266 |
Return
| Return on Equity | -66.12% |
|---|---|
| Return on Assets | -48.90% |
| Return on Invested Capital | -57.75% |
Valuation & Multiples
| P/E Ratio | -3.15 |
|---|---|
| PEG | 4.29 |
| Price to Sales | - |
| Price to Book Ratio | 5.3 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.15 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
$22.22 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$902,778
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 3.1848▲ 318.48% |
|---|---|
| Total Calls | 141,200▲ 143.03% |
| Total Puts | 449,700▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 41.43%▼ 4.15% |
|---|---|
| Total Invested | $65.21M▲ 37.16% |
| Investors Holding | 57▲ 19.00% |
ESG Score
No data